<DOC>
	<DOC>NCT00425061</DOC>
	<brief_summary>Primary purpose is to assess if IMA-638 is safe and improves asthma in subjects with persistent asthma.</brief_summary>
	<brief_title>Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<criteria>Generally healthy men and women with persistent asthma, 18 to 70 years of age, with body weight between 50 kg and 115 kg. History of treatment with a medium to high dose of inhaled corticosteroids (ICS), with or without longacting betaagonists (LABA), for at least 2 months prior to the screening visit and must remain constant during the study. FEV1 ≥ 55% to ≤ 80% predicted and demonstrated improvement in FEV1 (L) with inhaled albuterol (salbutamol) (reversibility) of ≥ 12%.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>